NOV 24, 2018 10:54 PM PST

New Anti-Malarial Drug Target in Cancer

WRITTEN BY: Nouran Amin

For decades, anti-malaria drugs--known as Chloroquines, have used to treat cancer. But the role in repurposing these drugs for slowing tumor growth have never been quite understood until a recent research study in Cancer Discovery.

Credit: NaturalNews.com

The research, carried at out Abramson Cancer Center of the University of Pennsylvania, identified the chloroquines specific target in cancer – an enzyme called PPT1. Identifying that particular enzyme has opened the doors for potential cancer treatments. “The discovery of this target is critical because chloroquines are currently being evaluated in clinical trials all over the world, including here at Penn, and this knowledge fundamentally changes the way we look at those trials,” says study co-senior author and associate professor--Dr Ravi K. Amaravadi of the Perelman School of Medicine at the University of Pennsylvania.

The enzyme, PPT1, controls the target of rapamycin (mTOR)—which is highly involved in the growth of cancer cells as well as another cellular process known as autophagy—a way for cancer cells to detoxify and repair themselves. The mechanisms of autophagy was discovered by Nobel Prize winner-- Yoshinori Ohsumi, watch the video below to learn more:

In previous studies, autophagy was found to provide nutrient support for mTOR to direct cancer growth while, interestingly, mTOR was found to shut down autophagy when nutrients aren’t needed. Using these studies, the researchers utilized CRISPR/Cas9 gene editing approach to knockout PPT1 from cancer cells and observe if the same effects in earlier research can be seen. Results showed that indeed removing ppt1 does slow tumor growth. “The edited cells look like they’ve been treated with a drug, and they grow significantly slower than the unedited cells,” Prof Amaravadi said. “We also compiled data from existing databases and found PPT1 is both highly expressed in most cancers and also associated with poor outcomes.”

These findings encouraged researchers to develop potent chloroquine known as DC661, that will take advantage of this novel treatment pathway.

“We now have a specific molecular target in cancer, as well as a potent way to reach it,” Prof Amaravadi said. “It not only provides new context for current clinical trials involving hydroxychloroquine, but also, with further development of these compounds toward clinical drug candidates, it opens the door for head-to-head testing of our compounds or their optimized derivatives versus current chloroquines to see which is more effective.”

Source: Drug Target Review

 

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
SEP 30, 2020
Cancer
Chemokines Could be the Key in Controlling Glioma Stem Cells
SEP 30, 2020
Chemokines Could be the Key in Controlling Glioma Stem Cells
The transformation of a healthy cell into a cancerous one often comes with a slew of cellular signaling changes.  T ...
OCT 12, 2020
Drug Discovery & Development
In vitro glycoengineering - Suitability for BioPharma manufacturing
OCT 12, 2020
In vitro glycoengineering - Suitability for BioPharma manufacturing
Introduction The importance of Fc glycosylation of monoclonal antibodies (mAbs) with regard to biological activity is wi ...
OCT 12, 2020
Cannabis Sciences
Can Cannabis Relieve Symptoms of Down Syndrome?
OCT 12, 2020
Can Cannabis Relieve Symptoms of Down Syndrome?
Increasing anecdotal and academic evidence has been emerging in recent years about the plethora of health benefits behin ...
OCT 03, 2020
Drug Discovery & Development
Treating Gut-Leakiness
OCT 03, 2020
Treating Gut-Leakiness
A drug called tofacitinib, also called Xeljanz , was found to treat permeability defects in the intestines. Tofacitinib ...
OCT 11, 2020
Drug Discovery & Development
Treating Connective Tissue Disorders
OCT 11, 2020
Treating Connective Tissue Disorders
Collaborative research efforts are geared to improving disease that affects connective tissues via innovative drug deliv ...
NOV 02, 2020
Cancer
Using an Anti-Malarial Drug to Fight Cancer
NOV 02, 2020
Using an Anti-Malarial Drug to Fight Cancer
Modern pharmaceutical companies spend billions of dollars and years of time developing the next big drug. What if they d ...
Loading Comments...